Equities

Kintor Pharmaceutical Ltd

Kintor Pharmaceutical Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.22
  • Today's Change0.00 / 0.00%
  • Shares traded785.50k
  • 1 Year change-68.88%
  • Beta0.2075
Data delayed at least 15 minutes, as of Jun 07 2024 09:09 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China. The Company is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The Company are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-1.15bn
  • Incorporated2018
  • Employees225.00
  • Location
    Kintor Pharmaceutical LtdNo.20 Songbei RoadSuzhou Industrial ParkSUZHOU 215123ChinaCHN
  • Phone+86 51 262639909
  • Websitehttps://www.kintor.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PuraPharm Corp Ltd406.86m-106.08m292.96m662.00--1.91--0.7201-0.2685-0.26851.030.38710.43741.044.21614,590.60-11.40-9.20-34.00-19.7053.2459.52-26.07-19.330.3046-2.020.7349---9.20-11.4111.76---13.68--
Hin Sang Group (Interntnl) Hldng Co Ltd92.79m-35.72m311.16m265.00--1.41--3.35-0.0327-0.03270.0850.2020.15242.299.49366,766.80-5.81-4.06-8.74-5.2655.9561.98-38.14-20.980.1129-1.150.5766---32.42-15.45-315.54---36.30--
Uni-Bio Science Group Ltd484.72m70.88m456.11m407.006.641.815.200.9410.01110.01110.07620.0411.382.6213.501,190,953.0020.181.4628.501.9781.0480.5914.621.231.7697.930.17960.0010.0829.0884.04--84.98--
Tianda Pharmaceuticals Ltd532.09m-24.16m494.51m863.00--0.835243.370.9294-0.0112-0.01120.24750.27540.53064.884.37616,557.40-2.49---3.84--48.02---4.70--0.8907-13.980.161--------------
Clover Biopharmaceuticals Ltd42.43m-149.76m512.33m387.00------12.07-0.1199-0.11990.034-0.61110.01160.00980.7449109,646.40-4.08---16.40--61.75---352.92--0.5281-1.45--------94.35------
Kintor Pharmaceutical Ltd0.00-1.15bn541.47m225.00--1.09-----2.67-2.670.001.110.000.1448--0.00-72.55-50.15-89.09-58.43---27.62---10,511.412.10--0.3566-------11.15---32.49--
Sirnaomics Ltd0.00-615.15m652.03m145.00--2.08-----8.09-8.090.003.590.00----0.00-70.91---71.22--------------0.6176------10.88------
Antengene Corporation Ltd72.75m-628.24m654.64m201.00--0.5278--9.00-1.02-1.020.11831.840.03580.97733.41361,960.90-30.91-53.57-36.46-58.9481.74---863.51-1,987.016.43--0.1491---57.97--3.38--202.03--
Genor Biopharma Holdings Ltd0.00-728.96m666.47m104.00--0.5096-----1.44-1.440.002.550.000.00--0.00-37.91-55.46-44.02-63.73--66.56---14,819.185.38--0.006---100.00--7.65---48.85--
Lee's Pharmaceutical Holdings Ltd1.05bn16.70m730.16m1.06k43.720.35814.680.69340.02840.02841.793.460.37131.8310.75996,247.900.703313.330.8817.7652.3561.921.8936.200.55263.900.09433.59-14.61-1.53-67.44-47.49-12.19-31.34
Jbm (Healthcare) Ltd610.30m97.99m775.44m258.008.560.82695.211.270.10870.10870.67861.120.44065.884.102,000,994.007.563.339.044.9347.7045.9717.1710.971.4522.150.121113.8128.1114.51131.906.14-5.09--
Transcenta Holding Limited58.21m-500.02m776.75m215.00--0.6974--13.34-1.23-1.230.1432.550.02812.051.49270,738.20-24.17---33.97--26.74---859.01--1.20-32.870.285---47.15---13.72------
Pak Fah Yeow International Ltd259.16m105.04m788.45m102.007.511.037.013.040.3370.3370.83162.460.29952.8822.182,540,765.0012.143.9912.604.1884.4580.7940.5321.276.9010.080.0062100.6876.0612.94250.6623.0218.83-8.06
Data as of Jun 07 2024. Currency figures normalised to Kintor Pharmaceutical Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

2.11%Per cent of shares held by top holders
HolderShares% Held
GF Fund Management Co., Ltd.as of 31 Dec 20234.43m0.99%
Caitong Fund Management Co., Ltd.as of 30 Jun 20233.04m0.68%
Penghua Fund Management Co., Ltd.as of 31 Dec 20231.14m0.25%
China Universal Asset Management Co., Ltd.as of 31 Dec 2023392.00k0.09%
SSgA Funds Management, Inc.as of 09 May 2024168.00k0.04%
Bosera Asset Management Co., Ltd.as of 31 Dec 2023130.00k0.03%
Dimensional Fund Advisors LPas of 31 Jan 202465.00k0.02%
Hwabao WP Fund Management Co., Ltd.as of 31 Dec 202358.50k0.01%
The Vanguard Group, Inc.as of 31 Jan 202315.06k0.00%
E Fund Management Co., Ltd.as of 31 Dec 202314.50k0.00%
More ▼
Data from 30 Jun 2023 - 30 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.